SCHEMBL24036483

SCHEMBL24036483

CS(=O)(=O)NCCn1nc(-c2ccc(OC(F)F)nc2)ccc1=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MET P08581 2/20 0.35
▸ HRH3 Q9Y5N1 3/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ FPR2 P25090 2/20 0.34
▸ FPR1 P21462 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23495408 0.84 KDM4E (0.43) PTGESKDM4EMEN1KMT2AHSD17B10
SCHEMBL24036526 0.81 HRH3 (0.44) PTGESKDM4EMEN1KMT2AHSD17B10
SCHEMBL26160815 0.78 MET (0.51) KDM4EMEN1KMT2AHSD17B10TP53
SCHEMBL23513145 0.77 POLB (0.46) KDM4EMEN1KMT2AHSD17B10TP53
SCHEMBL24035603 0.76 TP53 (0.46) KDM4EMEN1KMT2AHSD17B10TP53
SCHEMBL23495270 0.75 POLB (0.49) KDM4EMEN1KMT2AHSD17B10TP53
SCHEMBL24029946 0.75 KDM4E (0.43) PTGESKDM4EMEN1KMT2AHSD17B10
SCHEMBL26999003 0.75 PDE4B (0.54) MEN1KMT2ATP53METHRH3
SCHEMBL23297366 0.74 HDAC1 (0.45) PTGESKDM4EMEN1KMT2ATP53
SCHEMBL29776802 0.74 HDAC1 (0.45) PTGESKDM4EMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4149621-B1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS INC (US) 2024-10-30 — — EP disclosed
US-20230150977-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230150977-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230150977-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-05-18 — — US disclosed
WO-2021231572-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150977-A1 PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, IL1B, IL1RN PTGES 310/4885KDM4E 3412/4885MEN1 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback